[{"id":"2010f340-13a7-4993-8d47-1c65e48c1ea8","acronym":"REALL CD9","url":"https://clinicaltrials.gov/study/NCT06649253","created_at":"2025-02-26T08:07:55.242Z","updated_at":"2025-02-26T08:07:55.242Z","phase":"","brief_title":"Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse","source_id_and_acronym":"NCT06649253 - REALL CD9","lead_sponsor":"Rennes University Hospital","biomarkers":" CD9","pipe":"","alterations":" ","tags":["CD9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2035","primary_completion_date":" 02/01/2035","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2024-12-27"},{"id":"6b069ddb-3d44-4c51-aafc-c9dbf27dc3ef","acronym":"AALL0433","url":"https://clinicaltrials.gov/study/NCT00381680","created_at":"2021-01-18T01:19:36.490Z","updated_at":"2024-07-02T16:35:12.895Z","phase":"Phase 3","brief_title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00381680 - AALL0433","lead_sponsor":"Children's Oncology Group","biomarkers":" MYC","pipe":" | ","alterations":" MYC translocation","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Kidrolase (L-asparaginase) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-26"},{"id":"d5f97284-f241-4922-aff7-91252d0fa774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01700946","created_at":"2021-01-18T07:23:42.396Z","updated_at":"2024-07-02T16:36:03.318Z","phase":"Phase 2","brief_title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT01700946","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • clofarabine • mitoxantrone • Oncaspar liquid (pegaspargase) • Vumon (teniposide) • mercaptopurine • vinblastine • Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/15/2013","start_date":" 04/15/2013","primary_txt":" Primary completion: 07/24/2021","primary_completion_date":" 07/24/2021","study_txt":" Completion: 07/24/2021","study_completion_date":" 07/24/2021","last_update_posted":"2022-09-28"},{"id":"d81c169d-027d-49d9-bff6-559eec0984c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00061945","created_at":"2021-09-05T08:53:17.801Z","updated_at":"2024-07-02T16:36:11.082Z","phase":"Phase 1/2","brief_title":"Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00061945","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD52","pipe":"","alterations":" ","tags":["CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • cyclophosphamide • Campath (alemtuzumab) • vincristine • daunorubicin • leucovorin calcium • mercaptopurine • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 302","initiation":"Initiation: 06/01/2003","start_date":" 06/01/2003","primary_txt":" Primary completion: 12/01/2007","primary_completion_date":" 12/01/2007","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2022-05-03"},{"id":"6c736254-f89e-430a-94b8-4a5fec2da23a","acronym":"AALL0622","url":"https://clinicaltrials.gov/study/NCT00720109","created_at":"2022-04-24T08:54:47.098Z","updated_at":"2024-07-02T16:36:46.051Z","phase":"Phase 2/3","brief_title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00720109 - AALL0622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 07/14/2008","start_date":" 07/14/2008","primary_txt":" Primary completion: 12/31/2014","primary_completion_date":" 12/31/2014","study_txt":" Completion: 03/31/2020","study_completion_date":" 03/31/2020","last_update_posted":"2020-04-13"},{"id":"2d2d34a0-23cf-419a-9544-2fde51a15352","acronym":"","url":"https://clinicaltrials.gov/study/NCT00036738","created_at":"2021-01-18T00:01:50.693Z","updated_at":"2025-02-25T16:21:32.662Z","phase":"Phase 2","brief_title":"Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib","source_id_and_acronym":"NCT00036738","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/13/2001","start_date":" 07/13/2001","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2020-01-29"},{"id":"f098b0c9-04d9-4c7d-8399-1bb7e2d2b40a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01093586","created_at":"2021-01-18T04:19:20.928Z","updated_at":"2025-02-25T16:23:22.361Z","phase":"Phase 2","brief_title":"Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT01093586","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" KMT2A • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • busulfan • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2019-01-23"},{"id":"cba3d40a-123e-4492-a695-2917d5296d11","acronym":"","url":"https://clinicaltrials.gov/study/NCT00867529","created_at":"2021-01-18T03:18:45.194Z","updated_at":"2024-07-02T16:37:15.153Z","phase":"Phase 2","brief_title":"Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma","source_id_and_acronym":"NCT00867529","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 03/26/2015","study_completion_date":" 03/26/2015","last_update_posted":"2018-01-02"},{"id":"7e7e3870-8e4a-4338-a848-70b1c1bcda3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00052520","created_at":"2021-01-18T00:05:50.007Z","updated_at":"2024-07-02T16:37:23.993Z","phase":"Phase 1/2","brief_title":"Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation","source_id_and_acronym":"NCT00052520","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" ABL1 • BCR • CD8 • IGH • WT1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD8 • IGH • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/01/2002","start_date":" 09/01/2002","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2017-03-29"},{"id":"770106d8-745b-4d75-bebe-01c85063b36a","acronym":"AALL12B3","url":"https://clinicaltrials.gov/study/NCT01540578","created_at":"2021-01-18T06:30:38.218Z","updated_at":"2024-07-02T16:37:32.028Z","phase":"","brief_title":"Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01540578 - AALL12B3","lead_sponsor":"Children's Oncology Group","biomarkers":" RUNX1 • ETV6","pipe":"","alterations":" ","tags":["RUNX1 • ETV6"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-05-18"}]